Pacherille Angela M, Viernes Dennis R, Pedicone Chiara, Fernandes Sandra, Dungan Otto M, Dormann Shawn, Wallach Daniel R, Sudan Raki, Brooks Robbie, Russo Christopher M, Howard Kyle T, Cosgrove Michael S, Kerr William G, Chisholm John D
Department of Chemistry, Syracuse University, 111 College Place, Syracuse, NY, 13244, USA.
Department of Microbiology & Immunology, SUNY Upstate Medical University, 766 Irving Avenue, Syracuse, NY, 13210, USA.
ChemMedChem. 2025 Apr 14;20(8):e202400597. doi: 10.1002/cmdc.202400597. Epub 2025 Feb 13.
The SH2-containing inositol phosphatase (SHIP) has become an actively researched therapeutic target for a number of disorders, including Alzheimer's Disease, Graft-vs-Host disease, obesity and cancer. Analogs of the aminosteroid SHIP inhibitor 3α-aminocholestane (3AC) have been synthesized and tested. Analogs with improved water solubility have been identified. Deletion of the C17 alkyl group from the cholestane skeleton improves water solubility, however these compounds inhibit both SHIP1 and SHIP2. Enzyme kinetics imply that these molecules are competitive inhibitors of SHIP, binding at a site near where the substrate binds to the phosphatase. A model of the binding of the inhibitors within the active site of SHIP1 is proposed to explain the structure activity studies. Overall this work provides more water soluble aminosteroid pan-SHIP1/2 inhibitors that can be used for future studies of SHIP activity.
含SH2结构域的肌醇磷酸酶(SHIP)已成为针对多种疾病(包括阿尔茨海默病、移植物抗宿主病、肥胖症和癌症)进行积极研究的治疗靶点。已合成并测试了氨基甾体SHIP抑制剂3α-氨基胆甾烷(3AC)的类似物。已鉴定出具有改善水溶性的类似物。从胆甾烷骨架中删除C17烷基可提高水溶性,然而这些化合物会同时抑制SHIP1和SHIP2。酶动力学表明这些分子是SHIP的竞争性抑制剂,在底物与磷酸酶结合位点附近的一个位点结合。提出了SHIP1活性位点内抑制剂结合的模型来解释结构活性研究。总体而言,这项工作提供了更多水溶性氨基甾体泛SHIP1/2抑制剂,可用于未来SHIP活性的研究。